Vital Farms (Nasdaq: VITL) closed at $8.17 on October 21, 2026, giving up all of the 16.7% jump that followed a September 16 Axios Pro report that the pasture-raised egg brand was exploring a sale or take-private deal. Colin King, a value investor on X, prefers Cal-Maine Foods, calls branded eggs "still highly cyclical" and guesses Cal-Maine will eventually buy Vital Farms. The test is third-quarter results on November 3, 2026, when Vital Farms must show the second-half recovery its guidance needs.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Ticker and exchange: Vital Farms, VITL on the Nasdaq; prices in U.S. dollars.
- The call: Colin King (@valuedontlie) is skeptical of Vital Farms as a standalone stock but sees it as a likely takeover target; posted October 14, 2026 at $8.91.
- Size: 42,931,522 shares on August 3, 2026, about $351 million at $8.17, by our math.
- Guidance: 2026 net revenue of $775 million to $800 million and adjusted EBITDA of $0 to $10 million, reaffirmed August 6.
- First half: net revenue $353.2 million and an adjusted EBITDA loss of $21.6 million (10-Q).
- Balance sheet: $21.2 million of cash at June 28; a $125 million term loan at SOFR plus 7.50% and a $60 million asset-based facility closed in August.
- Catalyst: Q3 results before the open on Tuesday, November 3, 2026, call at 8:30 a.m. ET.
Is Vital Farms a good bet right now?
The bull case is a strong brand at a low price, plus takeover talk. Vital Farms says it grew retail dollar share of shell eggs by more than 200 basis points in the second quarter even as category prices fell.
The bear case is the math the guidance requires. To reach the guide, Vital Farms needs $421.8 million to $446.8 million of second-half revenue, 19% to 27% more than the first half, and $21.6 million to $31.6 million of second-half adjusted EBITDA, by our math.
Why are investors bullish on Vital Farms?
- Distribution. Management guided to 170 to 175 total distribution points in the fourth quarter, its biggest yearly gain since the 2020 IPO.
- Supply reset. Management said farmer contract amendments right-sized supply, which it expects to sharply cut the costly excess-egg sales that hit the second quarter.
- Lower costs. Staff cuts in May and July lowered annual SG&A by about $6 million to $7 million.
- Possible deal. The Axios Pro report put a sale on the table. We found no company announcement confirming a process.
Who's making this call and why?
Colin King writes about spin-offs, buyouts and value stocks and runs a newsletter. Asked to compare the two egg producers, he replied that in a downturn "you want to own the best balance sheet and low cost producer," and added: "My guess is CALM will scoop up VITL at some point in the future." He has posted bullishly on Cal-Maine.
Track record. In our tracking, Colin King is 11-8 (a .579 win rate) on 19 calls scored at 180 days against the S&P 500, with an average edge of +35.1 points, ranked No. 5. One large winner drives most of that average. See the scoreboard.
Other voices:
- Gabriel Osorio-Mazzilli, who says he worked in equity research, said on October 22: "I went looking for AI-proof stocks and ended up buying an egg company." He sells a paid write-up on the thesis.
- Calvin Blissett pushed back on the cyclical label, asking whether the point of the brand is to insulate Vital Farms from the egg cycle.
Who disagrees?
Alan Galecki of Financial-Engineering.net is bearish. On September 14 he listed the cash drain, the covenant waiver and the expensive secured loan, adding: "Liens on all assets." The filings back the key points:
- Covenant. Vital Farms was out of compliance with a fixed charge coverage covenant at June 28 and needed a lender waiver (10-Q).
- Losses. Second-quarter revenue fell 10.1% to $166.0 million, gross margin dropped to 6.6% from 38.9%, and the net loss was $31.1 million.
- Buyback gone. The board ended the stock repurchase program on August 3, 2026.
- Analysts. TD Cowen kept a Hold rating and cut its target to $8 from $11 on October 13 (Benzinga).
What are the key facts to verify?
- The Q2 2026 results release for guidance, margins and the new loans.
- The 10-Q for the June quarter for the waiver, cash, share count and loan terms.
- The Q3 date announcement.
- Axios's Dan Primack on the report of strategic alternatives.
What would prove it right or wrong?
Right (for the takeover view): a buyer emerges, or Vital Farms keeps losing money and needs a partner, as Colin King expects.
Wrong: Q3 shows positive adjusted EBITDA, distribution gains lift volumes, and Vital Farms reaches its guide alone, which would undercut both the cyclical worry and the need for a sale.
This is journalism and commentary, not investment advice. We hold no position unless stated.